港股异动 | 云顶新耀-B(1952.HK)涨4.47% 旗下乳腺癌药品获美国FDA批准使用
格隆汇4月9日丨云顶新耀-B(1952.HK)涨4.47%,报81.85港元,总市值240亿港元。云顶新耀发布公告,美国食品药品管理局(FDA)完全批准了吉利德科学公司旗下药物Trodelvy®(通用名:sacituzumab govitecan-hziy)用于治疗至少接受过两线或以上既往治疗的局部不可切除晚期或者转移性三阴性乳腺癌,至少其中之一为转移性疾病。吉利德科学公司是公司的合作伙伴。在与吉利德科学公司签署的授权引进协议中,公司在大中华区、南韩和部分东南亚国家享有针对所有癌症适应症开发、注册和商业化sacituzumab govitecan-hziy的独家权利。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.